Will Martin Assumes Role as President and Chief Executive Officer of IRRAS
Stockholm, July 1, 2021 - IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Will Martin has formally assumed the role of President and Chief Executive Officer (CEO), which comes as part of a planned succession process first announced in April 2021. Kleanthis G. Xanthopoulos, Ph.D., will step down as CEO and will remain on the Company’s Board of Directors.
Will Martin joined IRRAS as Chief Commercial Officer in 2018. Prior to IRRAS, he most recently served as General Manager of the Peripheral Vascular devices business for Philips Healthcare, Vice President of Commercial Operations at AtheroMed, Inc. prior to its acquisition by Volcano Corporation, and held other key leadership roles at other life science companies. He holds a BA degree from The University of Notre Dame and an MBA from Johns Hopkins University and also served as a Lieutenant in the United States Navy.
“It has been a tremendous honor to serve as the CEO of IRRAS, and I am incredibly proud of the team and what we have accomplished together,” said Dr. Xanthopoulos. “We have made meaningful progress to strengthen all elements of the company, and now, we are solely focused on commercial execution and acceleration. Will is the right leader to lead IRRAS into this next phase of growth.”
“I am incredibly excited and humbled to lead IRRAS during this important period,” said Martin. “We have now treated more than 200 patients with our IRRAflow system at more than 30 leading institutions, and we now have IRRAflow systems in place in 18 countries across 4 continents. As COVID restrictions lessen globally, our products are helping more critically ill patients each day, and I look forward to positioning the company to best support hospitals and investors around the world.”
About IRRAS
IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Sten Gustafsson
IR
sten.gustafsson@irras.com
+46 102 11 5172
The information was released for public disclosure, through the agency of the contact person above, on July 1, 2021 at 08:30 (CET).
